1. Generics Bulletin

Mylan has biosimilar aspirations for Botox

 
• By Dean Rudge

Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.

Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.

Under the firms’ global collaboration and license agreement, Mylan and Revance plan to work together to gain regulatory approval in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Who’s Hired? Rosemont Gains A Chairperson But Loses A CEO

 
• By Dave Wallace

In our latest roundup of off-patent industry appointments, we see management changes at UK liquids specialist Rosemont, a push into biosimilars from Korea’s Daewoong, and fresh appointments at firms including Meitheal, Celltrion, Accord, Alvotech, Civica and Centrient.

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Amgen Stands Firm On IV Checkpoint Inhibitor Biosimilars

 
• By Dean Rudge

Amgen continues to advance its intravenous biosimilar programs for key immuno-oncology agents, including its ABP 234 biosimilar to Keytruda and ABP 206 biosimilar to Opdivo, despite growing interest in subcutaneous formulations enabled by hyaluronidase technology.